|2026年7月20日星期一| NO.1 康希诺:核心疫苗产品申请扩充适用年龄范围 7月19日晚间,康希诺公告称,其核心产品“曼海欣®”(ACYW135群脑膜炎球菌多糖结合疫苗)的药品补充申请已获国家药监局受理,申请将适用人群从“3月龄~6周岁”扩大至“3月龄~17周岁”。 点评:本次申请若能获批,将直接拓宽目标接种人群,显著提升产品的市场空间与销售天花板。该疫苗为康希诺商业化核心品种之一,...
Source Link|2026年7月20日星期一| NO.1 康希诺:核心疫苗产品申请扩充适用年龄范围 7月19日晚间,康希诺公告称,其核心产品“曼海欣®”(ACYW135群脑膜炎球菌多糖结合疫苗)的药品补充申请已获国家药监局受理,申请将适用人群从“3月龄~6周岁”扩大至“3月龄~17周岁”。 点评:本次申请若能获批,将直接拓宽目标接种人群,显著提升产品的市场空间与销售天花板。该疫苗为康希诺商业化核心品种之一,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.